Home Nephro Research Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma

Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma

Credits to the Source Link Obum
Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma
  • 1.

    Coppin, C., Kollmannsberger, C., Le, L., Porzsolt, F. & Wilt, T. J. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int. 108, 1556–1563 (2011).

  • 2.

    van Beijnum, J. R., Nowak-Sliwinska, P., Huijbers, E. J., Thijssen, V. L. & Griffioen, A. W. The great escape; the hallmarks of resistance to anti-angiogenic therapy. Pharm. Rev. 67, 441–461 (2015).

  • 3.

    Smith, I., Procter, M., Gelber, R. D., Guillaume, S., Feyereislova, A., Dowsett, M. et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369, 29–36 (2007).

  • 4.

    Druker, B. J., Guilhot, F., O’Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408–2417 (2006).

  • 5.

    Nassif, E., Thibault, C., Vano, Y., Fournier, L., Mauge, L., Verkarre, V. et al. Sunitinib in kidney cancer: 10 years of experience and development. Expert Rev. Anticancer Ther. 17, 129–142 2017).

  • 6.

    Flaherty, K. T., Manola, J. B., Pins, M., McDermott, D. F., Atkins, M. B., Dutcher, J. J. et al. BEST: a randomized phase ii study of vascular endothelial growth factor, raf kinase, and mammalian target of rapamycin combination targeted therapy with bevacizumab, sorafenib, and temsirolimus in advanced renal cell carcinoma-A trial of the ECOG-ACRIN Cancer Research Group (E2804). J. Clin. Oncol. 33, 2384–2391 (2015).

  • 7.

    Motzer, R. J., Hutson, T. E., Glen, H., Michaelson, M. D., Molina, A., Eisen, T. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 16, 1473–1482 (2015).

  • 8.

    Rini, B. I., Bellmunt, J., Clancy, J., Wang, K., Niethammer, A. G., Hariharan, S. et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J. Clin. Oncol. 32, 752–759 (2014).

  • 9.

    Negrier, S., Gravis, G., Perol, D., Chevreau, C., Delva, R., Bay, J. O. et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol. 12, 673–680 (2011).

  • 10.

    Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116–1127 (2019).

  • 11.

    Motzer, R. J., Tannir, N. M., McDermott, D. F., Aren Frontera, O., Melichar, B., Choueiri, T. K. et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).

  • 12.

    Albiges, L., Choueiri, T., Escudier, B., Galsky, M., George, D., Hofmann, F. et al. A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. Eur. Urol. 67, 100–110 (2015).

  • 13.

    Nowak-Sliwinska, P., Weiss, A., Ding, X., Dyson, P. J., van den Bergh, H., Griffioen, A. W. et al. Optimization of drug combinations using Feedback System Control. Nat. Protoc. 11, 302–315 (2016).

  • 14.

    Weiss, A., Berndsen, R. H., Ding, X., Ho, C. M., Dyson, P. J., van den Bergh, H. et al. A streamlined search technology for identification of synergistic drug combinations. Sci. Rep. 5, 14508 (2015).

  • 15.

    Leary, M., Heerboth, S., Lapinska, K. & Sarkar, S. Sensitization of drug resistant cancer cells: a matter of combination therapy. Cancers 10, 483 (2018).

  • 16.

    Silva, A., Lee, B.-Y., Clemens, D. L., Kee, T., Ding, X., Ho, C.-M. et al. Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model. Proc. Natl Aca. Sci. USA 113, 172–179 (2016)

  • 17.

    Weiss, A. & Nowak-Sliwinska, P. Current trends in multidrug optimization: an alley of future successful treatment of complex disorders. SLAS Technol. 22, 254–275 (2017).

  • 18.

    Berndsen, R. H., Weiss, A., Abdul, U. K., Wong, T. J., Meraldi, P., Griffioen, A. W. et al. Combination of ruthenium(II)-arene complex [Ru(eta(6)-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity. Sci. Rep. 7, 43005 (2017).

  • 19.

    Weiss, A., Le Roux-Bourdieu, M., Zoetemelk, M., Ramzy, G. M., Rausch, M., Harry, D. et al. Identification of a synergistic multi-drug combination active in cancer cells via the prevention of spindle pole clustering. Cancers (Basel). 11, 1612 (2019)

  • 20.

    Gavine, P. R., Mooney, L., Kilgour, E., Thomas, A. P., Al-Kadhimi, K., Beck, S. et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 72, 2045–2056 (2012).

  • 21.

    Naing, A., Aghajanian, C., Raymond, E., Olmos, D., Schwartz, G., Oelmann, E. et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br. J. Cancer 107, 1093–1099 (2012).

  • 22.

    Sarker, D., Ang, J. E., Baird, R., Kristeleit, R., Shah, K., Moreno, V. et al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 21, 77–86 (2015).

  • 23.

    Dymond, A. W., Howes, C., Pattison, C., So, K., Mariani, G., Savage, M. et al. Metabolism, excretion, and pharmacokinetics of selumetinib, an MEK1/2 inhibitor, in healthy adult male subjects. Clin. Ther. 38, 2447–2458 (2016).

  • 24.

    Zoetemelk, M., Rausch, M., Colin, D. J., Dormond, O. & Nowak-Sliwinska, P. Short-term 3D culture systems of various complexity for treatment optimization of colorectal carcinoma. Sci. Rep. 9, 7103 (2019).

  • 25.

    Mason, E. F. & Rathmell, J. C. Cell metabolism: an essential link between cell growth and apoptosis. Biochim. Biophys. Acta 1813, 645–654 (2011).

  • 26.

    Huang, D., Ding, Y., Luo, W. M., Bender, S., Qian, C. N., Kort, E. et al. Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Cancer Res. 68, 81–88 (2008).

  • 27.

    Guo, H., German, P., Bai, S., Barnes, S., Guo, W., Qi, X. et al. The PI3K/AKT Pathway and Renal Cell Carcinoma. J. Genet. genomics = Yi chuan xue bao. 42, 343–353 (2015).

  • 28.

    Hattori, S., Kanda, S. & Harita, Y. Tyrosine kinase signaling in kidney glomerular podocytes. J. Signal Transduct. 2011, 317852 (2011).

  • 29.

    Gotink, K. J., Broxterman, H. J., Labots, M., de Haas, R. R., Dekker, H., Honeywell, R. J. et al. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin. Cancer Res. 17, 7337–7346 (2011).

  • 30.

    Nowak-Sliwinska, P., Weiss, A., van Beijnum, J. R., Wong, T. J., Kilarski, W. W., Szewczyk, G. et al. Photoactivation of lysosomally sequestered sunitinib after angiostatic treatment causes vascular occlusion and enhances tumor growth inhibition. Cell Death Dis. 6, e1641 (2015).

  • 31.

    Butz, H., Ding, Q., Nofech-Mozes, R., Lichner, Z., Ni, H. & Yousef, G. M. Elucidating mechanisms of sunitinib resistance in renal cancer: an integrated pathological-molecular analysis. Oncotarget 9, 4661–4674 (2017).

  • 32.

    Adar, Y., Stark, M., Bram, E. E., Nowak-Sliwinska, P., van den Bergh, H., Szewczyk, G. et al. Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers. Cell Death Dis. 3, e293 (2012).

  • 33.

    Buono, R. & Longo, V. D. Starvation, Stress Resistance, and Cancer. Trends Endocrinol. Metab. 29, 271–280 (2018).

  • 34.

    VanHook, A. M. Starving cancer cells to death. Sci. Signal. 11, eaau9719 (2018).

  • 35.

    Gozgit, J. M., Squillace, R. M., Wongchenko, M. J., Miller, D., Wardwell, S., Mohemmad, Q. et al. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother. Pharmacol. 71, 1315–1323 (2013).

  • 36.

    Cai, W., Song, B. & Ai, H. Combined inhibition of FGFR and mTOR pathways is effective in suppressing ovarian cancer. Am. J. Transl. Res. 11, 1616–1625 (2019).

  • 37.

    Scheller, T., Hellerbrand, C., Moser, C., Schmidt, K., Kroemer, A., Brunner, S. M. et al. mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma. Br. J. Cancer 112, 841–850 (2015).

  • 38.

    Berndsen, R. H., Castrogiovanni, C., Weiss, A., Rausch, M., Dallinga, M. G., Miljkovic-Licina, M. et al. Anti-angiogenic effects of crenolanib are mediated by mitotic modulation independently of PDGFR expression. Br. J. Cancer 121, 139–149 (2019).

  • 39.

    Horn, T., Ferretti, S., Ebel, N., Tam, A., Ho, S., Harbinski, F. et al. High-order drug combinations are required to effectively kill colorectal cancer cells. Cancer Res. 76, 6950 (2016).

  • 40.

    Kamli, H., Glenda, G. C., Li, L., Vesey, D. A. & Morais, C. Characterisation of the morphological, functional and molecular changes in sunitinib-resistant renal cell carcinoma cells. J. Kidney Cancer Vhl. 5, 1–9 (2018).

  • 41.

    Hatakeyama, H., Fujiwara, T., Sato, H., Terui, A. & Hisaka, A. Investigation of metabolomic changes in sunitinib-resistant human renal carcinoma 786-O cells by capillary electrophoresis-time of flight mass spectrometry. Biol. Pharm. Bull. 41, 619–627 (2018).

  • 42.

    Dehghani, M., Brobey, R. K., Wang, Y., Souza, G., Amato, R. J. & Rosenblatt, K. P. Klotho inhibits EGF-induced cell migration in Caki-1 cells through inactivation of EGFR and p38 MAPK signaling pathways. Oncotarget 9, 26737–26750 (2018).

  • 43.

    Kretschmer, A., Zhang, F., Somasekharan, S. P., Tse, C., Leachman, L., Gleave, A. et al. Stress-induced tunneling nanotubes support treatment adaptation in prostate cancer. Sci. Rep. 9, 7826 (2019).

  • 44.

    Mittal, R., Karhu, E., Wang, J. S., Delgado, S., Zukerman, R., Mittal, J. et al. Cell communication by tunneling nanotubes: Implications in disease and therapeutic applications. J. Cell Physiol. 234, 1130–1146 (2019).

  • 45.

    Sahu, P., Jena, S. R. & Samanta, L. Tunneling nanotubes: a versatile target for cancer therapy. Curr. Cancer Drug Targets 18, 514–521 (2018).

  • 46.

    Rustom, A., Saffrich, R., Markovic, I., Walther, P. & Gerdes, H. H. Nanotubular highways for intercellular organelle transport. Science. 303, 1007–1010 (2004).

  • 47.

    Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).

  • 48.

    Zhu, Y., Xu, L., Zhang, J., Hu, X., Liu, Y., Yin, H. et al. Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells. Cancer Sci. 104, 1052–1061 (2013).

  • 49.

    Wettersten, H. I., Hee Hwang, S., Li, C., Shiu, E. Y., Wecksler, A. T., Hammock, B. D. et al. A novel p21 attenuator which is structurally related to sorafenib. Cancer Biol. Ther. 14, 278–285 (2013).

  • 50.

    Batchelder, C. A., Martinez, M. L., Duru, N., Meyers, F. J. & Tarantal, A. F. Three dimensional culture of human renal cell carcinoma organoids. PLoS ONE 10, e0136758–e0136758 (2015).

  • 51.

    Miller, C. P., Tsuchida, C., Zheng, Y., Himmelfarb, J. & Akilesh, S. A 3D human renal cell carcinoma-on-a-chip for the study of tumor angiogenesis. Neoplasia 20, 610–620 (2018).

  • 52.

    Makhov, P., Joshi, S., Ghatalia, P., Kutikov, A., Uzzo, R. G. & Kolenko, V. M. Resistance to systemic therapies in clear cell renal cell carcinoma: mechanisms and management strategies. Mol. Cancer Ther. 17, 1355–1364 (2018).

  • 53.

    Rini, B. I., McDermott, D. F., Hammers, H., Bro, W., Bukowski, R. M., Faba, B. et al. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. J. Immunother. Cancer 4, 81 (2016).

  • 54.

    Procopio, G., Ratta, R., de Braud, F. & Verzoni, E. Combination therapies for patients with metastatic renal cell carcinoma. Lancet Oncol. 19, 281–283 (2018).

  • 55.

    Huijbers, E. J., van Beijnum, J. R., Thijssen, V. L., Sabrkhany, S., Nowak-Sliwinska, P. & Griffioen, A. W. Role of the tumor stroma in resistance to anti-angiogenic therapy. Drug Resist Updat. 25, 26–37 (2016).

  • 56.

    Griffioen, A. W., Mans, L. A., de Graaf, A. M. A., Nowak-Sliwinska, P., de Hoog, C., de Jong, T. A. M. et al. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin. Cancer Res. 18, 3961–3971 (2012).

  • 57.

    Porta, C., Paglino, C., Imarisio, I., Canipari, C., Chen, K., Neary, M. et al. Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. BMC Cancer 11, 105 (2011).

  • 58.

    Bukowski, R. M. Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma. Expert Rev. Anticancer Ther. 10, 635–645 (2010).

  • 59.

    Tannir, N. M., Schwab, G. & Grünwald, V. Cabozantinib: an active novel multikinase inhibitor in renal cell carcinoma. Curr. Oncol. Rep. 19, 14 (2017).

  • 60.

    Berlow, N. E., Rikhi, R., Geltzeiler, M., Abraham, J., Svalina, M. N., Davis, L. E. et al. Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma. BMC Cancer 19, 593 (2019).

  • 61.

    Yang, Z. & Tam, K. Y. Combination strategies using EGFR-TKi in NSCLC Therapy: learning from the gap between pre-clinical results and clinical outcomes. Int. J. Biol. Sci. 14, 204–216 (2018).

  • 62.

    Cava, C., Bertoli, G. & Castiglioni, I. In silico identification of drug target pathways in breast cancer subtypes using pathway cross-talk inhibition. J. Transl. Med. 16, 154 (2018).

  • 63.

    Fumarola, C., Bozza, N., Castelli, R., Ferlenghi, F., Marseglia, G., Lodola, A., et al. Expanding the arsenal of FGFR inhibitors: a novel chloroacetamide derivative as a new irreversible agent with anti-proliferative activity against FGFR1-amplified lung cancer cell lines. Front. Oncol. 9, 179 (2019)

  • 64.

    Dhillon, A. S., Hagan, S., Rath, O. & Kolch, W. MAP kinase signalling pathways in cancer. Oncogene 26, 3279–3290 (2007).

  • 65.

    Tolcher, A. W., Peng, W. & Calvo, E. Rational approaches for combination therapy strategies targeting the MAP kinase pathway in solid tumors. Mol. Cancer Ther. 17, 3–16 (2018).

  • 66.

    Caumanns, J. J., van Wijngaarden, A., Kol, A., Meersma, G. J., Jalving, M., Bernards, R. et al. Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma. Cancer Lett. 461, 102–111 (2019).

  • 67.

    Hainsworth, J. D., Spigel, D. R., Burris, H. A. 3rd, Waterhouse, D., Clark, B. L. & Whorf, R. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J. Clin. Oncol. 28, 2131–2136 (2010).

  • 68.

    Faes, S., Santoro, T., Demartines, N. & Dormond, O. Evolving significance and future relevance of anti-angiogenic activity of mTOR inhibitors in cancer therapy. Cancers 9, 152 (2017).

  • 69.

    Bamias, A., Karavasilis, V., Gavalas, N., Tzannis, K., Samantas, E., Aravantinos, G. et al. The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study. Int. J. Clin. Oncol. 24, 411–419 (2019).

  • 70.

    Pal, K., Madamsetty, V. S., Dutta, S. K., Wang, E., Angom, R. S. & Mukhopadhyay, D. Synchronous inhibition of mTOR and VEGF/NRP1 axis impedes tumor growth and metastasis in renal cancer. NPJ Precis. Oncol. 3, 31 (2019).

  • Source Link

    Related Posts

    Leave a Comment

    This website uses cookies to improve your experience. We will assume you are ok with this, but you can opt-out if you wish. Accept Read More

    %d bloggers like this: